1. In Vivo

Deals Shaping The Medical Industry, September 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

Endo International PLC (branded and generic drugs, devices, and services) has sold its uropathology business HealthTronics Laboratory Solutions Inc. (HLS) to cancer diagnostics firm Metamark Genetics Inc. (Aug.)

HLS’s offerings include the SimplifID prostate biopsy kit, FISH molecular cytology tests for bladder cancer, triple stain immunohistochemistry services, and other uropathology products. With path labs located in Georgia and Pennsylvania, and client practices in 41 states across the US, HLS has the wide market reach that Metamark is looking for as it continues to develop and prepares to launch its ProMark genomic- and proteomic-based prostate cancer test later this year. Endo acquired HLS’ parent HealthTronics Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By Ian Taylor

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 
• By Urtė Fultinavičiūtė

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.